 CAMBRIDGE, Mass., April 01, 2022 GLOBE NEWSWIRE -- Foghorn Therapeutics Inc. Nasdaq: FHTX, a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced the company will have an oral and late-breaking poster presentation at the upcoming American Association for Cancer Research AACR Annual Meeting, taking place April 8-13, 2022, in New Orleans, Louisiana. Presentations include preclinical data supporting the clinical development of the novel BAF inhibitor FHD-286 for the treatment of acute myeloid leukemia AML, Myelodysplastic syndromes MDS and metastatic uveal melanoma UM. 